Skip to Content

Cysview Approval History

  • FDA approved: Yes (First approved May 28th, 2010)
  • Brand name: Cysview
  • Generic name: hexaminolevulinate
  • Dosage form: for Intravesical Solution
  • Previous name: Hexvix
  • Company: Photocure ASA
  • Treatment for: Diagnosis and Investigation

Cysview (hexaminolevulinate HCl) is an optical imaging agent indicated for use in the cystoscopic detection of non-muscle invasive papillary cancer of the bladder.

Development History and FDA Approval Process for Cysview

Jun  2, 2010Approval Cysview (Hexaminolevulinate HCl) Approved by the FDA for Cystoscopic Detection of Papillary Bladder Cancer
Nov 23, 2009FDA has posted an Advisory Committee meeting with Photocure to discuss Hexvix NDA
Sep  1, 2009Photocure ASA (NO) - Hexvix has been granted priority review by the FDA
Jul  1, 2009Photocure submits application for marketing approval for Hexvix in USA to the FDA
Apr 20, 2006FDA Requests More Information Related to Hexvix NDA

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.